BACKGROUND: The monoclonal antibody anti-epidermal growth factor receptor (EGFr) antibody-425, against the epidermal growth factor receptor, has the potential to bind specifically to gliomas and not normal brain tissue. A prospective study was conducted (1986-1988) to evaluate the use of Indium-111 (111In)-labeled anti-EGFr-425 in the localization of gliomas before radioimmunotherapy with Iodine-125 (125I)-labeled anti-EGFr-425. METHODS: Twenty-eight patients with intracranial neoplasms were injected intravenously with an average dose of 2.2 mCi 111In-labeled anti-EGFr-425. Planar and single-photon emission computed tomography scans were performed after 48 and 72 hours. Control studies also were performed in two cases with 111In-labeled Co 17-1A (an antibody to colorectal cancer) and in one case with unlabeled 111In chloride. RESULTS: The immunoscintigraphic findings were generally in good agreement with computerized tomographic findings. The definitive diagnosis was established by biopsy findings: 23 gliomas (1 Grade I, 5 Grade II, 6 Grade III, and 11 Grade IV), 1 meningioma, and 4 metastatic lesions. The localization of gliomas with 111In-labeled anti-EGF-425 had a sensitivity of 0.96, a specificity of 0.60 and an accuracy of 0.90. CONCLUSION: Immunoscintigraphy with 111-In labeled anti-EGFr-425 can be useful in the management of malignant gliomas, especially before radioimmunotherapy with 125I-labeled anti-EGFr-425.
BACKGROUND: The monoclonal antibody anti-epidermal growth factor receptor (EGFr) antibody-425, against the epidermal growth factor receptor, has the potential to bind specifically to gliomas and not normal brain tissue. A prospective study was conducted (1986-1988) to evaluate the use of Indium-111 (111In)-labeled anti-EGFr-425 in the localization of gliomas before radioimmunotherapy with Iodine-125 (125I)-labeled anti-EGFr-425. METHODS: Twenty-eight patients with intracranial neoplasms were injected intravenously with an average dose of 2.2 mCi 111In-labeled anti-EGFr-425. Planar and single-photon emission computed tomography scans were performed after 48 and 72 hours. Control studies also were performed in two cases with 111In-labeled Co 17-1A (an antibody to colorectal cancer) and in one case with unlabeled 111In chloride. RESULTS: The immunoscintigraphic findings were generally in good agreement with computerized tomographic findings. The definitive diagnosis was established by biopsy findings: 23 gliomas (1 Grade I, 5 Grade II, 6 Grade III, and 11 Grade IV), 1 meningioma, and 4 metastatic lesions. The localization of gliomas with 111In-labeled anti-EGF-425 had a sensitivity of 0.96, a specificity of 0.60 and an accuracy of 0.90. CONCLUSION: Immunoscintigraphy with 111-In labeled anti-EGFr-425 can be useful in the management of malignant gliomas, especially before radioimmunotherapy with 125I-labeled anti-EGFr-425.
Authors: Marleen van Oosten; Lucia Ma Crane; Joost Bart; Fijs W van Leeuwen; Gooitzen M van Dam Journal: Transl Oncol Date: 2011-04-01 Impact factor: 4.243
Authors: Maria J W D Vosjan; Lars R Perk; Rob C Roovers; Gerard W M Visser; Marijke Stigter-van Walsum; Paul M P van Bergen En Henegouwen; Guus A M S van Dongen Journal: Eur J Nucl Med Mol Imaging Date: 2011-01-06 Impact factor: 9.236
Authors: Susanna W L de Geus; Leonora S F Boogerd; Rutger-Jan Swijnenburg; J Sven D Mieog; Willemieke S F J Tummers; Hendrica A J M Prevoo; Cornelis F M Sier; Hans Morreau; Bert A Bonsing; Cornelis J H van de Velde; Alexander L Vahrmeijer; Peter J K Kuppen Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488
Authors: H Modjtahedi; T Hickish; M Nicolson; J Moore; J Styles; S Eccles; E Jackson; J Salter; J Sloane; L Spencer; K Priest; I Smith; C Dean; M Gore Journal: Br J Cancer Date: 1996-01 Impact factor: 7.640
Authors: D J J M de Gouw; M Rijpkema; T J J de Bitter; V M Baart; C F M Sier; S Hernot; G M van Dam; I D Nagtegaal; B R Klarenbeek; C Rosman; R S van der Post Journal: Mol Diagn Ther Date: 2020-04 Impact factor: 4.074